Retina Global is a US based 501(c)(3) nonprofit that is focused on finding sustainable solutions to the ever-increasing issues with retinal diseases in underserved areas around the world.
Genentech announced results from the Phase II BOULEVARD study, which is evaluating subjects with vision loss from diabetic macular edema (DME), where treatment with intravitreal RG7716 was observed to be clinically meaningful and statistically significant in improvement of visual acuity gains compared with ranibizumab alone.
